Sierra Natl BK Tehachapi Calif (MM) (NASDAQ:SIRT)
Historical Stock Chart
From Jul 2019 to Jul 2024
![Click Here for more Sierra Natl BK Tehachapi Calif (MM) Charts. Click Here for more Sierra Natl BK Tehachapi Calif (MM) Charts.](/p.php?pid=staticchart&s=N%5ESIRT&p=8&t=15)
Sirtris Pharmaceuticals, Inc. (NASDAQ: SIRT), a biopharmaceutical
company focused on discovering and developing small molecule drugs to
treat diseases of aging, announced today announced that it will report
financial results for the second quarter of 2007 on Monday, August 13,
2007, after the U.S. financial markets close.
Management will provide an update on the Company and discuss second
quarter results via conference call on Monday, August 13, 2007, at 4:30
p.m. EDT. To access the call, please dial 800-289-0572 (domestic) or
913-981-5543 (international) five minutes prior to the start time and
provide the passcode 2478956. A replay of the call will be available
from 6:00 p.m. EDT on August 13, 2007 until August 24, 2007. To access
the replay, please dial 888-203-1112 (domestic) or 719-457-0820
(international), and provide the passcode 2478956.
A live audio webcast of the call also will be available on the
"Investors" section of the Company's website, www.sirtrispharma.com.
An archived webcast will be available on the Sirtris website
approximately one hour after the call and will be archived for 14 days.
About Sirtris Pharmaceuticals
Sirtris Pharmaceuticals is a biopharmaceutical company focused on
discovering and developing proprietary, orally available, small molecule
drugs with the potential to treat diseases associated with aging,
including metabolic diseases such as Type 2 Diabetes. Our drug
candidates are designed to mimic certain beneficial health effects of
calorie restriction, without requiring a change in eating habits, by
activation of sirtuins, a recently discovered class of enzymes that
control the aging process. The company's headquarters are in Cambridge,
Massachusetts.
This press release contains forward-looking statements within the
meaning of the Private Securities Litigation Reform Act of 1995
concerning Sirtris Pharmaceuticals. These forward-looking statements
about future expectations, plans and prospects of Sirtris
Pharmaceuticals involve significant risks, uncertainties and
assumptions, including risks related to the lack of results that would
provide a basis for predicting whether any of the Company’s
product candidates will be safe or effective, or receive regulatory
approval, the possibility that results of pre-clinical studies are not
necessarily predictive of clinical trial results, the Company's
potential inability to initiate and complete pre-clinical studies and
clinical trials for its product candidates, the fact that none of the
Company's product candidates has received regulatory approvals, the
potential inability of the Company to gain market acceptance of the
Company's product candidates, and those other risks factors that can be
found in the Company's filings with the Securities and Exchange
Commission. Actual results may differ materially from those Sirtris
Pharmaceuticals contemplated by these forward-looking statements.
Sirtris Pharmaceuticals does not undertake to update any of these
forward-looking statements to reflect a change in its views or events or
circumstances that occur after the date of this release.